COMP <GO>
UNCY vs NERV // EV/EBITDA & P/E VALUATION
Unicycive Therapeutics Inc. (NASDAQ) VS. Minerva Neurosciences Inc (NASDAQ) • 15-METRIC TALLY: UNCY 1
— NERV 1
■ METRIC PARITY
LAST: $3.74 (-1.84%) • MKT CAP: $106.1M
valuation
—
LAST: $2.32 (+3.57%) • MKT CAP: $107.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UNCY VS. NERV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UNCY | NERV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -12.63% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.5 | 37.8 | +2.68 | UNCY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $106.1M | $107.0M | -$826.0K | NERV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UNCY REV | NERV REV | UNCY GROSS % | NERV GROSS % | UNCY FCF | NERV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$31.3M | -$13.5M |
| FY 2024 | $0 | $0 | — | — | -$28.6M | -$19.6M |
| FY 2023 | $675.0K | $0 | — | — | -$18.3M | -$14.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UNCY // BETA —
NERV // BETA —